KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EBITDA (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed EBITDA for 7 consecutive years, with $22.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 24.77% to $22.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $87.5 million through Dec 2025, up 32.87% year-over-year, with the annual reading at $91.7 million for FY2025, 30.34% up from the prior year.
  • EBITDA hit $22.7 million in Q4 2025 for GoodRx Holdings, up from $14.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $26.8 million in Q2 2025 to a low of -$38.3 million in Q3 2023.
  • Historically, EBITDA has averaged $7.1 million across 5 years, with a median of $11.5 million in 2021.
  • Biggest YoY gain for EBITDA was 552.38% in 2023; the steepest drop was 1152.85% in 2023.
  • Year by year, EBITDA stood at $11.8 million in 2021, then tumbled by 85.22% to $1.7 million in 2022, then crashed by 1152.85% to -$18.3 million in 2023, then surged by 199.41% to $18.2 million in 2024, then grew by 24.77% to $22.7 million in 2025.
  • Business Quant data shows EBITDA for GDRX at $22.7 million in Q4 2025, $14.6 million in Q3 2025, and $26.8 million in Q2 2025.